** Shares of Neurotech International NTI.AX rise 6.5% to A$0.033
** Stock set for strongest session since March 18, if current gains hold
** European Commission gives "orphan drug" designation to biopharmaceutical firm's NTI64 drug aimed at treating Rett Syndrome, a neurodevelopmental disorder that affects motor and communication skills
** European Commission grants "orphan drug" designation to promote medicine development for rare diseases affecting no more than 5 in 10,000 people in the European Union
** Co says "orphan" status gives it a range of incentives including 10-year market exclusivity, reduced regulatory fees and access to EU research funding
** Stock down 40% YTD, including current session's moves
(Reporting by Nikita Maria Jino in Bengaluru)
((Nikita.Jino@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.